CN106620894B - 一种可核磁共振显像体内植入材料及其制备方法和应用 - Google Patents
一种可核磁共振显像体内植入材料及其制备方法和应用 Download PDFInfo
- Publication number
- CN106620894B CN106620894B CN201611064629.8A CN201611064629A CN106620894B CN 106620894 B CN106620894 B CN 106620894B CN 201611064629 A CN201611064629 A CN 201611064629A CN 106620894 B CN106620894 B CN 106620894B
- Authority
- CN
- China
- Prior art keywords
- magnetic resonance
- nuclear magnetic
- resonance imaging
- spinning
- pet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000463 material Substances 0.000 title claims abstract description 102
- 238000001727 in vivo Methods 0.000 title claims abstract description 37
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims description 18
- 238000002513 implantation Methods 0.000 title abstract description 13
- 238000009987 spinning Methods 0.000 claims abstract description 43
- 238000005481 NMR spectroscopy Methods 0.000 claims abstract description 37
- 239000007943 implant Substances 0.000 claims abstract description 35
- 229920000642 polymer Polymers 0.000 claims abstract description 27
- 230000004044 response Effects 0.000 claims abstract description 19
- 239000002861 polymer material Substances 0.000 claims abstract description 18
- 239000002131 composite material Substances 0.000 claims abstract description 6
- 239000012528 membrane Substances 0.000 claims abstract description 5
- 210000000779 thoracic wall Anatomy 0.000 claims abstract description 5
- 206010019909 Hernia Diseases 0.000 claims abstract description 4
- 210000003792 cranial nerve Anatomy 0.000 claims abstract description 4
- 230000006837 decompression Effects 0.000 claims abstract description 4
- 210000000744 eyelid Anatomy 0.000 claims abstract description 4
- 210000003903 pelvic floor Anatomy 0.000 claims abstract description 4
- 230000008439 repair process Effects 0.000 claims abstract description 4
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 56
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 56
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 55
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 48
- 239000000243 solution Substances 0.000 claims description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
- 239000011259 mixed solution Substances 0.000 claims description 30
- 239000000835 fiber Substances 0.000 claims description 28
- -1 polyethylene terephthalate Polymers 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 22
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 20
- 238000010041 electrostatic spinning Methods 0.000 claims description 18
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 16
- 238000003860 storage Methods 0.000 claims description 14
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 7
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 4
- 230000002980 postoperative effect Effects 0.000 claims description 3
- 210000003128 head Anatomy 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000000465 moulding Methods 0.000 claims description 2
- 238000004804 winding Methods 0.000 claims 4
- 238000007493 shaping process Methods 0.000 abstract description 6
- 238000001514 detection method Methods 0.000 abstract description 4
- 230000008859 change Effects 0.000 abstract description 3
- 238000013329 compounding Methods 0.000 abstract description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 21
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 21
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 20
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 20
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 20
- 239000004743 Polypropylene Substances 0.000 description 19
- 229920002301 cellulose acetate Polymers 0.000 description 19
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 19
- 239000004926 polymethyl methacrylate Substances 0.000 description 19
- 229920001155 polypropylene Polymers 0.000 description 19
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 239000011572 manganese Substances 0.000 description 15
- 230000007613 environmental effect Effects 0.000 description 13
- 239000002270 dispersing agent Substances 0.000 description 11
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- MEANOSLIBWSCIT-UHFFFAOYSA-K gadolinium trichloride Chemical compound Cl[Gd](Cl)Cl MEANOSLIBWSCIT-UHFFFAOYSA-K 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- MAYVZUQEFSJDHA-UHFFFAOYSA-N 1,5-bis(methylsulfanyl)naphthalene Chemical compound C1=CC=C2C(SC)=CC=CC2=C1SC MAYVZUQEFSJDHA-UHFFFAOYSA-N 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- NNMXSTWQJRPBJZ-UHFFFAOYSA-K europium(iii) chloride Chemical compound Cl[Eu](Cl)Cl NNMXSTWQJRPBJZ-UHFFFAOYSA-K 0.000 description 9
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 230000005291 magnetic effect Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 7
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- 229920001400 block copolymer Polymers 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 229920001410 Microfiber Polymers 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 229910001938 gadolinium oxide Inorganic materials 0.000 description 4
- 229940075613 gadolinium oxide Drugs 0.000 description 4
- CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 150000002632 lipids Chemical group 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- AMWRITDGCCNYAT-UHFFFAOYSA-L manganese oxide Inorganic materials [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 3
- 229920005615 natural polymer Polymers 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 150000002038 dysprosium compounds Chemical class 0.000 description 2
- 229910003440 dysprosium oxide Inorganic materials 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002178 europium compounds Chemical class 0.000 description 2
- 229910001940 europium oxide Inorganic materials 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000003302 ferromagnetic material Substances 0.000 description 2
- 239000002657 fibrous material Substances 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 150000002251 gadolinium compounds Chemical class 0.000 description 2
- SQORATIMOBOFKR-UHFFFAOYSA-H gadolinium(3+);oxalate Chemical compound [Gd+3].[Gd+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O SQORATIMOBOFKR-UHFFFAOYSA-H 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229940074045 glyceryl distearate Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 229940099607 manganese chloride Drugs 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 150000002697 manganese compounds Chemical class 0.000 description 2
- GEYXPJBPASPPLI-UHFFFAOYSA-N manganese(III) oxide Inorganic materials O=[Mn]O[Mn]=O GEYXPJBPASPPLI-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 150000003502 terbium compounds Chemical class 0.000 description 2
- 229910003451 terbium oxide Inorganic materials 0.000 description 2
- GFISHBQNVWAVFU-UHFFFAOYSA-K terbium(iii) chloride Chemical compound Cl[Tb](Cl)Cl GFISHBQNVWAVFU-UHFFFAOYSA-K 0.000 description 2
- SCRZPWWVSXWCMC-UHFFFAOYSA-N terbium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Tb+3].[Tb+3] SCRZPWWVSXWCMC-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- KXJGSNRAQWDDJT-UHFFFAOYSA-N 1-acetyl-5-bromo-2h-indol-3-one Chemical compound BrC1=CC=C2N(C(=O)C)CC(=O)C2=C1 KXJGSNRAQWDDJT-UHFFFAOYSA-N 0.000 description 1
- STCBHSHARMAIOM-UHFFFAOYSA-N 1-methyl-1h-imidazol-1-ium;chloride Chemical compound Cl.CN1C=CN=C1 STCBHSHARMAIOM-UHFFFAOYSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- FTFFOIWLBWQKGM-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;manganese Chemical compound [Mn].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O FTFFOIWLBWQKGM-UHFFFAOYSA-N 0.000 description 1
- ROGIWVXWXZRRMZ-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1 ROGIWVXWXZRRMZ-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010053942 Cerebral haematoma Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010020523 Hydromyelia Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- WTBIAPVQQBCLFP-UHFFFAOYSA-N N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O WTBIAPVQQBCLFP-UHFFFAOYSA-N 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042928 Syringomyelia Diseases 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000009443 Vascular Malformations Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- AGXUVMPSUKZYDT-UHFFFAOYSA-L barium(2+);octadecanoate Chemical group [Ba+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O AGXUVMPSUKZYDT-UHFFFAOYSA-L 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- NLQFUUYNQFMIJW-UHFFFAOYSA-N dysprosium(iii) oxide Chemical compound O=[Dy]O[Dy]=O NLQFUUYNQFMIJW-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- AEBZCFFCDTZXHP-UHFFFAOYSA-N europium(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Eu+3].[Eu+3] AEBZCFFCDTZXHP-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000009730 filament winding Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229920000141 poly(maleic anhydride) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920001707 polybutylene terephthalate Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229950008885 polyglycolic acid Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920005996 polystyrene-poly(ethylene-butylene)-polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 201000011096 spinal cancer Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 229920006132 styrene block copolymer Polymers 0.000 description 1
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L31/128—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Prostheses (AREA)
Abstract
本发明公开一种可核磁共振显像体内植入材料,所述植入材料由高分子材料与具有核磁共振特异性响应材料复合而成。所述高分子材料与具有核磁共振特异性响应材料的质量比为1:(10‑5~1.5)。通过调整核磁共振特异性响应材料的浓度与组合,实现在不同核磁共振扫描序列下具有特异性信号,在核磁共振下产生图像,纺丝后造形使材料根据实际需求形成多种外形,使该复合材料有效解决了现有高分子植入材料在人体内由于与周围组织无信号差别而不能获取植入材料信息的问题,手术植入后可通过无损伤检测获得植入物位置和外观变化等信息。应用范围包括颅神经减压垫片、盆底复合补片、下睑替代材料、疝气修补材料、人工胸壁、心脏补片、术后防粘连膜等。
Description
技术领域
本发明涉及医疗器械领域,更具体地,涉及一种可核磁共振显像体内植入材料及其制备方法和应用。
背景技术
核磁共振(Nuclear Magnetic Resonance,NMR)是指原子核在一定条件下与外磁场共振的物理现象,作为一种分析手段广泛应用于物理、化学生物等领域,到1973年才将它用于医学临床检测。为了避免与核医学中放射成像混淆,把它称为核磁共振成像(MagneticResonance Imaging,MRI)或磁共振成像或核磁共振显像。核磁共振(NMR)与磁共振成像(MRI)在磁共振基础理论、信号激发、弛豫时间等方面并无差异,通常对核磁共振与磁共振成像两概念不做区分。
核磁共振成像的基本工作原理是将人体置于特殊的磁场中,用无线电射频脉冲激发人体内氢原子核,引起氢原子核共振,并吸收能量。在停止射频脉冲后,氢原子核按特定频率发出射电信号,并将吸收的能量释放出来,被体外的接受器收集,经电子计算机处理获得图像,这一过程称为核磁共振成像。在医学方面,MRI利用人体内物质拥有不同弛豫时间的特点,通过施加射频信号可以得到人体的核磁共振图像,以此来达到区分、判断人体组织状态的目的。MRI提供的信息量不但大于医学影像学中的其他许多成像技术,而且不同于已有的成像技术,因此,它对疾病的诊断具有很大的潜在优势。它可以直接作出横断面、矢状面、冠状面和各种断面的体层图像,无电离辐射,对机体没有不良影响。MRI对检测脑内血肿、脑外血肿、脑肿瘤、颅内动脉瘤、动静脉血管畸形、脑缺血、椎管内肿瘤、脊髓空洞症和脊髓积水等颅脑常见疾病非常有效,同时对腰椎椎间盘后突、原发性肝癌等疾病的诊断也很有效。由于信号强度、采集方式以及原子核丰度的限制,医学核磁共振设备只能探测人体中氢原子的信号,且信号主要来自水质子与脂质子。
人体植入材料作为一种医疗器材已被大量用于医疗领域,高分子材料是现有人体植入材料的重要原料。由于原子核类型、核外电子屏蔽效应等因素的存在,一定频率、一定能量的射频脉冲仅能作用于进动频率匹配的原子核。基于人体的特点,核磁共振的信号主要源自于水分子与脂肪分子中的氢核。高分子材料包含大量非氢原子,且其中氢原子相对水质子与脂质子的外部电子环境差异巨大,不会被射频脉冲激发,或其弛豫时间仅为数十毫秒,小于核磁共振信号采集时间。因而,置入体内的高分子材料,通常在核磁共振下完全无信号,或被组织液浸润进而与周围组织无差别,致使术后很难观察植入的高分子材料在体内的状态,给进一步的治疗和诊断带来不便。
因此,探索一种具有核磁共振特异性响应且外形可控的核磁共振显像高分子基复合材料作为植入材料显得尤为重要。
发明内容
为了克服现有技术中高分子基体内植入材料不能在核磁共振下显像的问题,本发明提供一种在核磁共振下显像的体内植入材料。该材料由高分子材料与具有核磁共振特异性响应材料复合而成,在不同核磁共振扫描序列下具有与人体组织不同的特异性信号,在核磁共振下产生图像,有效解决了现有植入材料在人体内由于与周围环境组织无信号差从而不能获取植入材料信息的缺点。
本发明的另一目的在于提供一种上述核磁共振显像材料的制备方法,采用静电纺丝法将高分子材料与具有核磁共振特异性响应材料制成超细复合纤维。该方法简单可行、重复性好且可纺材料来源广泛,所得纤维材料具有直径超细、比表面积大的特点,且可根据实际需要制备出可控外形。
本发明的再一目的在于提供上述核磁共振显像体内植入材料的应用。
本发明的目的通过下属技术方案实现:
一种可核磁共振显像体内植入材料,所述植入材料由高分子材料与具有核磁共振特异性响应材料复合而成。
优选地,所述高分子材料与具有核磁共振特异性响应材料的质量比为1:(10-5~1.5)。
所述高分子材料为天然高分子材料,合成高分子材料,或天然高分子与合成高分子混合材料;
优选地,所述天然高分子材料聚乳酸、聚己内酯、聚乙交酯、聚丙交酯、聚羟基乙酸、透明质酸、纤维蛋白、丝蛋白、聚乙二醇、壳聚糖、胶原蛋白或明胶中的一种以上;
优选地,所述合成高分子材料为聚乙烯、聚丙烯、聚氯乙烯、聚苯乙烯、聚甲基丙烯酸甲酯、聚酰胺、聚碳酸酯、聚甲醛、聚对苯二甲酸丁二酯、聚对苯二甲酸乙二酯、醋酸纤维素、甲基纤维素、乙基纤维素、羟乙基纤维素、氰乙基纤维素、羟丙基纤维素、羟丙基甲基纤维素、羟乙基淀粉、羧甲基淀粉、聚乙烯吡咯烷酮、聚乙烯醇、聚丙烯腈、聚乙二醇-聚乳酸嵌段共聚物、聚乙二醇-聚己内酯嵌段共聚物、聚乙二醇-聚乙烯吡咯烷酮嵌段共聚物、聚苯乙烯-聚丁二烯嵌段共聚物、苯乙烯-丁二烯-苯乙烯三嵌段共聚物、聚苯乙烯-聚(乙烯-丁烯)-聚苯乙烯嵌段共聚物、苯乙烯-异戊二烯/丁二烯-苯乙烯嵌段共聚物或聚苯乙烯-聚丁二烯-聚苯乙烯嵌段共聚物中的一种以上。
优选地,所述具有核磁共振特异性响应材料为铕化合物、钆化合物、铽化合物、镝化合物、锰化合物、铁磁性材料、多元醇、甘油酯、甾醇化合物或脂肪酸中的一种以上。
更为优选地,所述铕化合物为氧化铕、氯化铕、纳米氧化铕或纳米氯化铕;所述钆化合物为钆二乙基三胺五乙酸螯合物、氧化钆、氯化钆、草酸钆、纳米氧化钆、纳米氯化钆或纳米草酸钆;所述铽化合物为氧化铽、氯化铽、纳米氧化铽或纳米氯化铽;所述镝化合物为氧化镝、氯化镝、纳米氧化镝或纳米氯化镝;所述锰化合物为四氧化三锰、氯化锰、纳米四氧化三锰、纳米氯化锰、柠檬酸螯合锰或乙二胺四乙酸锰;所述铁磁性材料为超顺磁性纳米氧化铁、磁性四氧化三铁、铁酸钠、柠檬酸螯合铁、氨基酸铁、乙二胺二邻苯基乙酸铁;所述多元醇为乙二醇、丙二醇或丙三醇;所述甘油酯为单硬脂酸甘油酯、双硬脂酸甘油酯或三硬脂酸甘油酯;所述甾醇化合物为胆甾醇、谷甾醇、豆甾醇、麦角甾醇或羊毛甾;所述脂肪酸为月桂酸、肉豆蔻酸、软脂酸、硬脂酸、花生酸、木蜡酸、亚油酸、亚麻酸、花生四烯酸、二十碳五烯酸或二十二碳六烯酸。
一种上述可核磁共振显像体内植入材料的制备方法,包括以下具体步骤:
S1.将高分子材料溶于溶剂中,搅拌得到均匀的浓度为1~30wt%的高分子溶液,然后加入具有核磁共振特异性响应材料混合,搅拌均匀得到纺丝混合溶液;
S2.将步骤S1所得纺丝混合溶液装入带有喷射头的储存容器中进行静电纺丝,静电纺丝的条件和参数范围为:高压静电电压范围为9~40kV,环境温度为15~40℃,空气相对湿度为30~95%,喷丝头与收丝装置的距离为5~50cm,用收丝装置进行收集并获得超细纤维;
S3.将步骤S2中收集到的超细纤维,按使用需要造型,室温下空气气氛密封保存,即得到可核磁共振显像体内植入材料。
优选地,步骤S1中所述溶剂为二氯甲烷、三氯甲烷、二氯乙烷、四氯乙烷、丙烯酸甲酯、四氢呋喃、甲基四氢呋喃、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、二甲基亚砜、乙醚、石油醚、丙酮、甲酸、乙酸、三氟乙酸、四氯化碳、二甲苯、甲苯、苯酚、氯苯、硝基苯、戊烷、正己烷、甲基环己烷、N-甲基吡咯烷酮、苯甲醚、甲醇、乙醇、1-丙醇、2-丙醇、1-丁醇、2-丁醇、戊醇、N-甲基吗啉-N-氧化物、氯化甲基咪唑盐或甲酚中的一种以上;当步骤S1中所述具有核磁共振特异性响应材料为纳米材料时,加入分散剂混合,所述分散剂为脂类分散剂、脂肪烃分散剂、金属皂类分散剂、聚多元醇类分散剂或酸酐分散剂。
更为优选地,所述脂类分散剂为单硬脂酸甘油酯、双硬脂酸甘油酯或三硬脂酸甘油酯;所述脂肪烃分散剂为直链烷烃,其化学通式为CnH2n+2,其中n=3~60;所述金属皂类分散剂为硬脂酸钡或硬脂酸锌;所述聚多元醇类分散剂为聚乙二醇或聚丙三醇;所述酸酐分散剂为水解聚马来酸酐。
优选地,步骤S2中所述收丝装置可为:(1)平板收丝装置,由一块平板构成,接地或与-30~-0.5kV负高压相连;或(2)滚筒收丝装置,由直径为5~30cm的滚筒与驱动电机组成,滚筒转速为50~3000r/min,滚筒接地或与-30~-0.5kV负高压相连。
上述可核磁共振显像体内植入材料在颅神经减压垫片、盆底复合补片、下睑替代材料、疝气修补片、人工胸壁、心脏补片、术后防粘连膜中的应用。
本发明通过选用不同的具有核磁共振特异性响应材料,获得具有不同核磁共振响应信号与强度的核磁共振显像体内植入材料。由于人体组织具有各自的T1、T2弛豫时间,在不同的扫描序列下,具有特定弛豫时间的组织能表现出明显的亮(高信号)或暗(低信号)的图像,如类似脂肪拥有长T2的组织,在T2平扫图像下会表现为较亮(高信号),而肝脏T2较短,则表现为较暗(低信号)。在人体内现有高分子植入材料与周围组织无信号差别,本发明有效解决了这种无信号差别的问题,手术植入后可通过无损伤MRI检测获得植入物位置和形状变化等信息,以实现跟踪和了解病患病情的目的。
与现有技术相比,本发明具有以下有益效果:
1.本发明的可核磁共振显像体内植入材料既保留了高分子材料本身的力学性能和生物学特性,又实现了在核磁共振下的显像效果。可以在核磁共振下获得显著区别于人体周围组织的图像,获得出植入材料的形状与体内位置等信息。
2.本发明采用静电纺丝法制备可核磁共振显像体内植入材料,该方法简单可行、重复性好且可纺材料来源广泛,所得纤维材料具有直径超细、比表面积大的特点,可根据实际需要制备出外形可控,且具有设计信号类型的核磁共振显像材料。
3.本发明通过选用不同的具有核磁共振特异性响应材料,获得具有不同核磁共振响应信号与强度的核磁共振显像材料,使可核磁共振显像体植入材料有效解决了在人体内由于现有高分子植入材料与周围组织无信号差别而不能获取植入材料信息的问题,手术植入后可通过无损伤MRI检测获得植入物位置和形状变化等信息,以实现跟踪和了解病患病情的目的。可在颅神经减压垫片、盆底复合补片、下睑替代材料、疝气修补片、人工胸壁、心脏补片、术后防粘连膜中得到广泛地应用。
附图说明
图1为实施例1中聚对苯二甲酸乙二酯(PET)/单硬脂酸甘油酯(GMS)体内植入材料贴附于脑部皮肤的T2平扫MRI图像。
图2为实施例1中聚对苯二甲酸乙二酯(PET)/单硬脂酸甘油酯(GMS)体内植入材料的实物照片。
图3为实施例2中聚对苯二甲酸乙二酯(PET)/丙三醇(GLY)体内植入材料贴附于脑部皮肤的T2平扫MRI图像。
图4为实施例3中聚对苯二甲酸乙二酯(PET)/单硬脂酸甘油酯(GMS)/超顺磁性纳米氧化铁(SPIO)体内植入材料的扫描电子显微镜照片。
具体实施方式
下面结合具体实施例进一步说明本发明的内容,但不应理解为对本发明的限制。
实施例1聚对苯二甲酸乙二酯(PET)/单硬脂酸甘油酯(GMS)体内植入材料的制备
1.将2g PET溶于7g二氯甲烷和7g三氟乙酸的混合溶剂,搅拌得到均匀的高分子溶液,然后将0.5g GMS加入到PET、二氯甲烷和三氟乙酸的高分子溶液中,搅拌至均匀,得到PET/GMS混合溶液;
2.取4ml步骤1所得PET/GMS混合溶液,装入带有喷丝头的储存容器内,设置静电纺丝装置,高压静电电压10kV,采用平板收丝装置收集,平板与-1kV负压相连,喷丝头与收集器间的距离为10cm,控制环境温度为20℃,环境湿度为35%,纺丝得到PET/GMS超细纤维。
3.将步骤2中收集到的PET/GMS超细纤维,造形为0.3cm*5cm*7cm薄片,干燥后室温下,空气气氛密封保存,即得到PET/GMS体内植入材料。图1是PET/GMS体内植入材料贴附于脑部皮肤的T2平扫MRI图像,可以见到眼部上方的高亮区即为PET/GMS可核磁显像材料;PET/GMS体内植入材料的实物如图2所示,可以看到,其为白色片状纤维膜,并可被塑形成其他形状。
实施例2聚对苯二甲酸乙二酯(PET)/丙三醇(GLY)体内植入材料的制备
1.将2g PET溶于7g二氯甲烷和7g三氟乙酸的混合溶剂,搅拌得到均匀的高分子溶液,然后将0.5g GLY加入PET、二氯甲烷和三氟乙酸的高分子溶液中,搅拌至均匀,得到PET/GLY混合溶液;
2.取4ml步骤1所得PET/GLY混合溶液,装入带有喷丝头的储存容器内,设置静电纺丝装置,高压静电电压12kV,采用平板收丝装置收集,平板与-5kV负压相连,喷丝头与收集器间的距离为10cm,控制环境温度为25℃,环境湿度为40%,纺丝得到PET/GLY超细纤维。
3.将步骤2中收集到的PET/GLY超细纤维,造形为10cm*3cm*5cm的长方体,干燥后室温下,空气气氛密封保存,即得到PET/GLY体内植入材料。图3为PET/GLY材料贴附于脑部皮肤的T2平扫MRI图像,可以见到眼部上方的高亮区即为PET/GLY可核磁显像材料。与图1对比可以看出T2平扫下,PET/GMS可核磁显像材料表现为比人体组织亮的高信号,PET/GLY核磁显像材料表现为比人体组织暗的低信号。
实施例3聚对苯二甲酸乙二酯(PET)/单硬脂酸甘油酯(GMS)/超顺磁性纳米氧化铁(SPIO)体内植入材料的制备
1.将2g PET溶于7g二氯甲烷和7g三氟乙酸的混合溶剂,搅拌得到均匀的高分子溶液,然后将0.3g GMS与0.002g SPIO加入到PET、二氯甲烷和三氟乙酸的高分子溶液中,搅拌至均匀,得到PET/GMS/SPIO混合溶液。
2.取4ml步骤1所得PET/GMS/SPIO混合溶液,装入带有喷丝头的储存容器内,设置静电纺丝装置,高压静电电压15kV,采用平板收丝装置收集,平板与大地相连,喷丝头与收集器间的距离为30cm,控制环境温度为30℃,环境湿度为60%,纺丝得到PET/GMS/SPIO超细纤维。
3.将步骤2中收集到的PET/GMS/SPIO超细纤维,造形为单层膜,干燥后室温下,空气气氛密封保存,即得到PET/GMS/SPIO体内植入材料。图4是PET/GMS/SPIO体内植入材料的扫描电镜照片,从图4中可见PET/GMS/SPIO纤维呈圆柱状、平均直径为300纳米左右。
实施例4聚对苯二甲酸乙二酯(PET)/三硬脂酸甘油酯(GTS)/氧化钆(Gd2O3)体内植入材料的制备
1.将20g PET溶于70g二氯甲烷和14g三氟乙酸的混合溶剂,搅拌得到均匀的高分子溶液,然后将2g GTS与0.003g Gd2O3加入PET、二氯甲烷和三氟乙酸的高分子溶液中,搅拌至均匀,得到PET/GTS/Gd2O3的混合溶液。
2.取4ml步骤1所得PET/GTS/Gd2O3混合溶液,装入带有喷丝头的储存容器内,设置静电纺丝装置,高压静电电压18kV,采用滚筒收丝装置收集,滚筒直径30cm,转速60r/min,滚筒与-1kV负压相连,喷丝头与收集器间的距离为25cm,控制环境温度为35℃,环境湿度为80%,纺丝得到PET/TMS/Gd2O3超细纤维。
3.将步骤2中收集到的PET/GTS/Gd2O3超细纤维,造形为单层膜,干燥后室温下,空气气氛密封保存,即得到PET/GTS/Gd2O3体内植入材料。
实施例5聚丙烯(PP)/双硬脂酸甘油酯(GDS)/氧化钆(Gd2O3)体内植入材料的制备
1.将1.5g PP溶于7.0g N,N-二甲基甲酰胺(DMF),搅拌得到均匀的高分子溶液,然后将0.2g GDS与0.001g的Gd2O3加入PP和DMF的高分子溶液中,搅拌至均匀,得到PP/GDS/Gd2O3混合溶液;
2.取4ml步骤1所得PP/GDS/Gd2O3混合溶液,装入带有喷丝头的储存容器内,设置静电纺丝装置,高压静电电压25kV,采用滚筒收丝装置收集,滚筒直径10cm,转速1500r/min,滚筒与-15kV负压相连,喷丝头与收集器间的距离为35cm,控制环境温度为40℃,环境湿度为93%,纺丝得到PP/GDS/Gd2O3超细纤维。
3.将步骤2中收集到的PP/GDS/Gd2O3超细纤维,造形为单层膜,干燥后室温下,空气气氛密封保存,即得到PP/GDS/Gd2O3体内植入材料。
实施例6聚丙烯(PP)/氯化铕(EuCl3)体内植入材料的制备
1.将24g PP溶于56g N,N-二甲基甲酰胺(DMF),搅拌得到均匀的高分子溶液,然后将0.005g EuCl3加入PP和DMF的高分子溶液中,搅拌至均匀,得到PP/EuCl3混合溶液。
2.取4ml步骤1所得PP/EuCl3混合溶液,装入带有喷丝头的储存容器内,设置静电纺丝装置,高压静电电压30kV,采用滚筒收丝装置收集,滚筒直径20cm,转速2000r/min,滚筒与-25kV负压相连,喷丝头与收集器间的距离为50cm,控制环境温度为25℃,环境湿度为70%,纺丝得到PP/EuCl3超细纤维。
3.将步骤2中收集到的PP/EuCl3超细纤维,造形为底面半径2cm,高5cm的圆柱体,干燥后室温下,空气气氛密封保存,即得到PP/EuCl3体内植入材料。
实施例7聚甲基丙烯酸甲酯(PMMA)/四氧化三锰(Mn3O4)体内植入材料的制备
1.将1g PMMA溶于9g N,N-二甲基甲酰胺(DMF),搅拌得到均匀的高分子溶液,然后将0.001g Mn3O4加入PMMA和DMF的高分子溶液中,搅拌至均匀,得到PMMA/Mn3O4混合溶液。
2.取4ml步骤1所得PMMA/Mn3O4混合溶液,装入带有喷丝头的储存容器内,设置静电纺丝装置,高压静电电压9kV,采用滚筒收丝装置收集,滚筒直径5cm,转速3000r/min,滚筒与-15kV负压相连,喷丝头与收集器间的距离为45cm,控制环境温度为25℃,环境湿度为65%,纺丝得到PMMA/Mn3O4超细纤维。
3.将步骤2中收集到的PMMA/Mn3O4超细纤维,造形为底面半径2cm,高5cm的圆柱体,干燥后室温下,空气气氛密封保存,即得到PMMA/Mn3O4体内植入材料。
实施例8聚甲基丙烯酸甲酯(PMMA)/氯化镝(DyCl3)体内植入材料的制备
1.将10g PMMA溶于120g N,N-二甲基甲酰胺(DMF),搅拌得到均匀的高分子溶液,然后将0.001g DyCl3加入到PMMA和DMF的高分子溶液中,搅拌至均匀,得到PMMA/DyCl3混合溶液。
2.取4ml步骤1所得PMMA/DyCl3混合溶液,装入带有喷丝头的储存容器内,设置静电纺丝装置,高压静电电压13kV,采用平板收丝装置收集,平板与-30kV负压相连,喷丝头与收集器间的距离为45cm,控制环境温度为35℃,环境湿度为30%,纺丝得到PMMA/DyCl3超细纤维。
3.将步骤2中收集到的PMMA/DyCl3超细纤维,造形为10cm*3cm*5cm的长方体,干燥后室温下,空气气氛密封保存,即得到PMMA/DyCl3体内植入材料。
实施例9醋酸纤维素(CA)/聚乙二醇(PEG)/超顺磁性纳米氧化铁(SPIO)体内植入材料的制备
1.将12g CA溶于50g N,N-二甲基乙酰胺(DMAc)和100g丙酮的混合溶剂,搅拌得到均匀的高分子溶液,然后将18g PEG与0.001g SPIO加入到CA、DMAc和丙酮的高分子溶液中,搅拌至均匀,得到CA/PEG/SPIO混合溶液;
2.取4ml步骤1所得CA/PEG/SPIO混合溶液,装入带有喷丝头的储存容器内,设置静电纺丝装置,高压静电电压25kV,采用平板收丝装置收集,平板与-7kV负压相连,喷丝头与收集器间的距离为40cm,控制环境温度为25℃,环境湿度为60%,纺丝得到CA//PEG/SPIO超细纤维。
3.将步骤2中收集到的CA/PEG/SPIO超细纤维,造形为单层膜,干燥后常温下,空气气氛密封保存,即得CA/PEG/SPIO体内植入材料。
实施例10聚乙烯吡咯烷酮(PVP)/四氧化三锰(Mn3O4)体内植入材料的制备
1.将20g PVP溶于80g无水乙醇,搅拌得到均匀的高分子溶液,然后将0.005g Mn3O4加入到PVP和无水乙醇的高分子溶液中,搅拌至均匀,得到PVP/Mn3O4混合溶液。
2.取4ml步骤1所得PVP/Mn3O4混合溶液,装入带有喷丝头的储存容器内,设置静电纺丝装置,高压静电电压13kV,采用平板收丝装置收集,平板与-8kV负压相连,喷丝头与收集器间的距离为15cm,控制环境温度为35℃,环境湿度为45%,纺丝得到PVP/Mn3O4超细纤维。
3.将步骤2中收集到的PVP/Mn3O4超细纤维,造形为底面半径2cm,高5cm的圆柱体,干燥后室温下,空气气氛密封保存,即得到PVP/Mn3O4体内植入材料。
实施例11聚乙烯吡咯烷酮(PVP)/钆二乙基三胺五乙酸(Gd-DTPA)体内植入材料的制备
1.将3g PVP溶于10g无水乙醇,搅拌得到均匀的高分子溶液,然后将0.003g Gd-DTPA加入到PVP和无水乙醇的高分子溶液中,搅拌至均匀,得到PVP/Gd-DTPA混合溶液。
2.取4ml步骤1所得PVP/Gd-DTPA混合溶液,装入带有喷丝头的储存容器内,设置静电纺丝装置,高压静电电压15kV,采用平板收丝装置收集,平板与-6kV负压相连,喷丝头与收集器间的距离为15cm,控制环境温度为40℃,环境湿度为45%,纺丝得到PVP/Gd-DTPA超细纤维。
3.将步骤2中收集到的PVP/Gd-DTPA超细纤维,造形为底面半径1cm,高3cm的圆柱体,干燥后室温下,空气气氛密封保存,即得到PVP/Gd-DTPA体内植入材料。
实施例12醋酸纤维素(CA)/氯化钆(GdCl3)体内植入材料的制备
1.将600g CA溶于670g N,N-二甲基乙酰胺(DMAc)和1330g丙酮的混合溶剂,搅拌得到均匀的高分子溶液,然后将0.006g GdCl3加入到CA、DMAc和丙酮的高分子溶液中,搅拌至均匀,得到CA/GdCl3混合溶液;
2.取4ml步骤1所得CA/GdCl3混合溶液,装入带有喷丝头的储存容器内,设置静电纺丝装置,高压静电电压20kV,采用平板收丝装置收集,平板与-6kV负压相连,喷丝头与收集器间的距离为40cm,控制环境温度为25℃,环境湿度为60%,纺丝得到CA/GdCl3超细纤维。
3.将步骤2中收集到的CA/GdCl3超细纤维,造形为单层膜,干燥后室温下,空气气氛密封保存,即得CA/GdCl3体内植入材料。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合和简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (4)
1.一种可核磁共振显像体内植入材料,其特征在于,所述植入材料由高分子材料与具有核磁共振特异性响应材料复合而成;所述高分子材料与具有核磁共振特异性响应材料的质量比为1:0.25;所述高分子材料为聚对苯二甲酸乙二酯,所述具有核磁共振特异性响应材料为单硬脂酸甘油酯或丙三醇;
所述的可核磁共振显像体内植入材料的制备方法,包括以下具体步骤:
S1. 将高分子材料聚对苯二甲酸乙二酯溶于溶剂中,搅拌得到均匀的浓度为1~30wt%的高分子溶液,然后加入具有核磁共振特异性响应材料单硬脂酸甘油酯或丙三醇混合,搅拌均匀得到纺丝混合溶液;
S2. 将步骤S1所得纺丝混合溶液装入带有喷射头的储存容器中进行静电纺丝,静电纺丝的条件和参数范围为:高压静电电压范围为9~40 kV,环境温度为15~40℃,空气相对湿度为30~95%,喷丝头与收丝装置的距离为5~50cm,用收丝装置进行收集并获得超细纤维;
S3. 将步骤S2中收集到的超细纤维,按使用需要造型,室温下空气气氛密封保存,即得到可核磁共振显像体内植入材料。
2.根据权利要求1所述的可核磁共振显像体内植入材料,其特征在于,步骤S1中所述溶剂为二氯甲烷和三氟乙酸。
3.根据权利要求1所述的可核磁共振显像体内植入材料,其特征在于,步骤S2中所述收丝装置为:(1)平板收丝装置,由一块平板构成,接地或与-30~-0.5kV负高压相连;或(2)滚筒收丝装置,由直径为5~30cm的滚筒与驱动电机组成,滚筒转速为50~3000r/min,滚筒接地或与-30~-0.5kV负高压相连。
4.权利要求1-3任一项所述的可核磁共振显像体内植入材料在颅神经减压垫片、盆底复合补片、下睑替代材料、疝气修补片、人工胸壁、心脏补片、术后防粘连膜中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611064629.8A CN106620894B (zh) | 2016-11-28 | 2016-11-28 | 一种可核磁共振显像体内植入材料及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611064629.8A CN106620894B (zh) | 2016-11-28 | 2016-11-28 | 一种可核磁共振显像体内植入材料及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106620894A CN106620894A (zh) | 2017-05-10 |
CN106620894B true CN106620894B (zh) | 2023-02-17 |
Family
ID=58812912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611064629.8A Active CN106620894B (zh) | 2016-11-28 | 2016-11-28 | 一种可核磁共振显像体内植入材料及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106620894B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111155197B (zh) * | 2020-01-10 | 2021-01-19 | 华南理工大学 | 一种磁性纤维材料及其制备方法和应用 |
CN113520627B (zh) * | 2021-07-23 | 2022-10-18 | 亚都控股集团有限公司 | 一种能够被多重智能识别的医用棉纱垫或纱布叠片及其制备方法 |
CN114796531B (zh) * | 2022-03-30 | 2023-08-18 | 华南理工大学 | 一种非金属温度响应性磁共振成像复合材料及其制备方法与应用 |
CN116590806A (zh) * | 2023-04-12 | 2023-08-15 | 华南理工大学 | 一种可磁共振显像的二元脂肪酸共晶复合纤维及其制备与应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101161705A (zh) * | 2006-10-13 | 2008-04-16 | 中国科学院化学研究所 | 功能性聚合物纳米复合材料及其制备方法和用途 |
CN101880917A (zh) * | 2010-02-05 | 2010-11-10 | 西安理工大学 | 一种制备纳米陶瓷纤维的方法 |
CN102294040A (zh) * | 2011-09-05 | 2011-12-28 | 同济大学 | 一种用于核磁共振成像和药物载体的磁性纳米聚合物囊泡及其制备方法 |
CN103550834A (zh) * | 2013-10-25 | 2014-02-05 | 北京大学 | 一种栓塞材料组合物及其制备方法和用途 |
CN103938288A (zh) * | 2014-04-10 | 2014-07-23 | 北京石油化工学院 | 脂肪酸相变储能发光材料及其纳米纤维的制备 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030100830A1 (en) * | 2001-11-27 | 2003-05-29 | Sheng-Ping Zhong | Implantable or insertable medical devices visible under magnetic resonance imaging |
US7483732B2 (en) * | 2004-04-15 | 2009-01-27 | Boston Scientific Scimed, Inc. | Magnetic resonance imaging of a medical device and proximate body tissue |
-
2016
- 2016-11-28 CN CN201611064629.8A patent/CN106620894B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101161705A (zh) * | 2006-10-13 | 2008-04-16 | 中国科学院化学研究所 | 功能性聚合物纳米复合材料及其制备方法和用途 |
CN101880917A (zh) * | 2010-02-05 | 2010-11-10 | 西安理工大学 | 一种制备纳米陶瓷纤维的方法 |
CN102294040A (zh) * | 2011-09-05 | 2011-12-28 | 同济大学 | 一种用于核磁共振成像和药物载体的磁性纳米聚合物囊泡及其制备方法 |
CN103550834A (zh) * | 2013-10-25 | 2014-02-05 | 北京大学 | 一种栓塞材料组合物及其制备方法和用途 |
CN103938288A (zh) * | 2014-04-10 | 2014-07-23 | 北京石油化工学院 | 脂肪酸相变储能发光材料及其纳米纤维的制备 |
Also Published As
Publication number | Publication date |
---|---|
CN106620894A (zh) | 2017-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106620894B (zh) | 一种可核磁共振显像体内植入材料及其制备方法和应用 | |
Zhao et al. | Magnetic bioinspired micro/nanostructured composite scaffold for bone regeneration | |
Zheng et al. | Nanofibrous nerve guidance conduits decorated with decellularized matrix hydrogel facilitate peripheral nerve injury repair | |
KR100762928B1 (ko) | 견 피브로인 나노섬유로 이루어진 부직포 형태의 골조직유도 재생용 차폐막 및 그 제조방법 | |
Li et al. | A novel 3D printing PCL/GelMA scaffold containing USPIO for MRI-guided bile duct repair | |
CN101507843B (zh) | 多用途外科生物补片材料 | |
RU2496525C2 (ru) | Биосовместимые продукты для визуализации магнитных частиц | |
Mertens et al. | USPIO-labeled textile materials for non-invasive MR imaging of tissue-engineered vascular grafts | |
Samal et al. | Biomimetic magnetic silk scaffolds | |
Datta et al. | Bioprinting of radiopaque constructs for tissue engineering and understanding degradation behavior by use of Micro-CT | |
CN106693081A (zh) | 一种可核磁共振显像材料的制备方法和应用 | |
Chen et al. | Preparation and characterization of 3D porous conductive scaffolds with magnetic resonance enhancement in tissue engineering | |
Liu et al. | Novel biodegradable polycaprolactone occlusion device combining nanofibrous PLGA/collagen membrane for closure of atrial septal defect (ASD) | |
CN110876818B (zh) | 一种促进骨修复材料plga降解的方法 | |
WO2023184905A1 (zh) | 一种非金属温度响应性磁共振成像复合材料及其制备方法与应用 | |
Jia et al. | One-step method to fabricate poly (ethylene terephthalate)/Gd (OH) 3 magnetic nanofibers towards MRI-active materials with high T1 relaxivity and long-term visibility | |
CN103741262B (zh) | 一种用于硬脑膜或硬脊膜修补的几丁糖纳米纤维膜及其制备方法与应用 | |
CN110279902A (zh) | 一种神经外科术后防粘连膜及其制备方法 | |
CN113967269B (zh) | 具有磁共振显影效果的可载药聚乙烯醇栓塞微球及其制备方法 | |
Zhang et al. | Vancomycin-loaded silk fibroin microspheres in an injectable hydrogel for chronic osteomyelitis therapy | |
EP1666077B1 (de) | Chirurgisches Trägermaterial mit Silberpartikeln, medizintechnisches Produkt enthaltend das Trägermaterial und Verfahren zur Detektion des Trägermaterials sowie von Adhäsionen | |
KR102115167B1 (ko) | 강도가 증가된 콜라겐/키틴 나노섬유 멤브레인 및 이의 제조 방법 | |
Wang et al. | Preparation of Nano Electrospinning Covered Stent and Its Application in the Treatment of Intracranial Aneurysm with CT Diagnosis | |
KR20150116941A (ko) | PVP-b-PCL 블록 공중합체를 포함하는 친수성 나노섬유 세포지지체 | |
Yang et al. | Enhanced contrast imaging with polyamide 6/Fe (OH) 3 nanofibrous scaffolds: A focus on high T1 relaxivity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231030 Address after: Room 202, No. 100 Liwan Road, Liwan District, Guangzhou City, Guangdong Province, 510130, self-made Q02 Patentee after: Guangzhou Qihua Biotechnology Co.,Ltd. Address before: EF building, Tian Hai business center, Lhasa, Tibet Patentee before: TIBET QIHUA BIOTECHNOLOGY CO.,LTD. |